Emerging Drug Developer: BrainCells

BrainCells

Remember when they used to say that you'd have all the brain cells you ever could have when you reached adulthood?

Turns out, they were wrong.

San Diego-based BrainCells has set out to find existing drugs that can spur the development of new neural stem cells, building on research that demonstrates that the process can have a therapeutic effect on a host of diseases of the central nervous system, including major-market targets like depression, anxiety and schizophrenia. And its platform technology is geared to spotlight the most likely drug candidates from a slate of therapies that have pushed past early-stage safety trials for other indications--a strategy that allows researchers to advance swiftly into mid-stage trials while striking up new research and development pacts with other biotech companies.

That's proven to be a winning argument for a high-profile group of venture funds. This morning BrainCells will announce its second round of $30 million, with MedImmune Ventures joining Bay City Capital, Oxford Bioscience Partners, Technology Partners, Pappas Ventures and Neuro Ventures in the round. Their money goes to the mid-stage development of BrainCells' lead candidate--BCI-540--and the hunt for more therapies that can advance quickly into Phase II. Article

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.